Jeff Yass’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-20,322
| Closed | -$186K | – | 11280 |
|
|
2019
Q4 | $186K | Buy |
20,322
+7,791
| +62% | +$94.7K | ﹤0.01% | 8824 |
|
|
2019
Q3 | $211K | Buy |
12,531
+2,449
| +24% | +$36.5K | ﹤0.01% | 8998 |
|
|
2019
Q2 | $136K | Buy |
+10,082
| New | +$151K | ﹤0.01% | 9442 |
|
|
2018
Q4 | – | Sell |
-27,954
| Closed | -$360K | – | 10452 |
|
|
2018
Q3 | $360K | Buy |
27,954
+7,838
| +39% | +$113K | ﹤0.01% | 7120 |
|
|
2018
Q2 | $363K | Buy |
20,116
+10,173
| +102% | +$205K | ﹤0.01% | 7464 |
|
|
2018
Q1 | $208K | Sell |
9,943
-4,779
| -32% | -$93.6K | ﹤0.01% | 8268 |
|
|
2017
Q4 | $334K | Buy |
+14,722
| New | +$342K | ﹤0.01% | 7407 |
|
|
2017
Q3 | – | Sell |
-11,867
| Closed | -$319K | – | 10002 |
|
|
2017
Q2 | $319K | Sell |
11,867
-2,419
| -17% | -$78.3K | ﹤0.01% | 7480 |
|
|
2017
Q1 | $479K | Buy |
+14,286
| New | +$526K | ﹤0.01% | 6565 |
|
|
2016
Q4 | – | Sell |
-6,133
| Closed | -$289K | – | 10423 |
|
|
2016
Q3 | $259K | Buy |
6,133
+660
| +12% | +$30.5K | ﹤0.01% | 7173 |
|
|
2016
Q2 | $354K | Sell |
5,473
-7,561
| -58% | -$465K | ﹤0.01% | 6693 |
|
|
2016
Q1 | $944K | Buy |
+13,034
| New | +$966K | ﹤0.01% | 5207 |
|
Other funds holding ZBIO
Jeff Yass's ZBIO Position: Q1 2020 in Review
Jeff Yass sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q1 2020, closing a stake of 20,322 shares — an estimated $186K sold.
Jeff Yass first reported a position in ZBIO in Q1 2016 and held it in 12 quarters. The position peaked at $944K in Q1 2016. 1 fund tracked by Wall St. Rank holds ZBIO as of Q1 2020.
- Jeff Yass reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Jeff Yass sold 20,322 ProShares UltraPro Short NASDAQ Biotechnology shares in Q1 2020, an estimated $186K.
- Jeff Yass first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q1 2016 and held it in 12 quarters.
- Jeff Yass's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $944K in Q1 2016.
- 1 fund tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q1 2020.
Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.